Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Pathogenic bacterium in gut microbiota” is not a single molecular entity but refers to any bacterial species within the human gastrointestinal tract that has been associated with disease. The term encompasses a diverse set of organisms—including but not limited to Klebsiella pneumoniae, Bacteroides fragilis, certain strains of Escherichia coli (such as EPEC and EHEC), Clostridium difficile, and others—that can cause infections or contribute to inflammatory conditions when present at high abundance or under dysbiotic conditions[1][4][5]. These organisms are classified based on their potential to cause harm rather than shared molecular features. Their presence is context-dependent; some may be harmless commensals under normal circumstances but become pathogenic if host defenses are compromised. Because “pathogenic bacterium in gut microbiota” does not refer to a unique molecule, receptor, enzyme, transporter, or other canonical therapeutic target class—and instead describes an ecological role within the complex community structure—it is not considered an appropriate entry for structured drug-target databases. Instead, each individual pathogen should be listed separately by its scientific name for precise targeting information[1][3]. In summary: This entry is too broad and non-specific for structured therapeutic targeting purposes. It should be replaced with entries corresponding to individual pathogenic bacterial species found within the human gastrointestinal tract.
Mechanisms depend on the specific drug and bacterial species; for example, antibiotics inhibit cell wall synthesis or protein synthesis in susceptible pathogens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacterium in gut microbiota.